9th IAS Conference on HIV Science (IAS 2017), Paris, France, 23-26 July 2017

第九届 IAS HIV 科学会议 (IAS 2017)，法国巴黎，2017 年 7 月 23-26 日

• 批准号: 9339774
• 负责人: Linda-Gail Gail Bekker
• 金额: $ 70万
• 依托单位: IAS
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-05-12 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9339774
• 关键词: AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Adherence; Adolescent; Adverse effects; Africa; Aging; Antiviral Agents; Area; Asia; Basic Science; Cardiovascular system; Caring; Central Asia; Cessation of life; Cities; Clinical Research; Clinical Sciences; Cognitive; Communities; Comorbidity; Continuity of Patient Care; Country; Data; Development; Discrimination; Disease remission; Eastern Europe; Ensure; Epidemic; Epidemiology; Europe; Financial Support; France; General Population; Goals; HIV; HIV Infections; HIV/TB; Hepatitis B; Hepatitis C; Human Rights; Human immunodeficiency virus test; Immune; Individual; Infection; Inflammation; Injecting drug user; International; Kidney; Knowledge; Leadership; Life; Life Expectancy; Link; Malaria; Malignant Neoplasms; Metabolic; Methods; Middle East; Nomads; Northern Africa; Oral; Paris, France; Pathogenesis; Pathway interactions; Patients; Pharmaceutical Preparations; Policies; Policy Maker; Politics; Population; Population Heterogeneity; Prevention; Preventive vaccine; Public Health; Refugees; Regimen; Research; Research Personnel; Research Priority; Science; Scientific Advances and Accomplishments; Scientist; Services; System; Technology; Testing; Time; Topical application; Translating; Translations; Treatment outcome; Tuberculosis; Vaccination; Vaccines; Viral; Viral hepatitis; Vision; anticancer research; base; bone; co-infection; cost effective; cost effectiveness; drug development; frontier; implementation research; implementation science; improved; innovation; insight; meetings; men who have sex with men; multidisciplinary; novel; novel marker; novel therapeutics; optimism; passive antibodies; pre-exposure prophylaxis; precision medicine; prevent; programs; research and development; response; scale up; sex; social stigma; symposium; synergism; therapeutic vaccine; tool; transgender; treatment strategy; trend; uptake

Project Summary - Significant scientific advances were made in the last few years that contribute to better HIV prevention and treatment outcomes and increased cost-effectiveness but major challenges remain that could undermine the attainment of the global goal to end AIDS as a public health threat: Better treatment and vaccines remain an urgent challenge to address the HIV/TB epidemic. Much more is needed to effect scale up and optimize treatment strategies in high-burden regions. Globally challenges remain in reaching ambitious targets across the continuum of care. Concrete innovations are urgently needed to improve HIV testing and its uptake and to retain individuals successfully in life-long care. This is particularly evident in adolescent populations. IAS 2017 will contribute to addressing some of the continuing challenges in HIV prevention, treatment and care in a scientific program that will integrate innovative approaches, such as the active application of avant-garde technologies in basic science and implementation research, and precision medicine as a bridging theme. France’s key role in HIV science and the strong political will enabling a rapid translation of science into policy, along with the country’s strong links with countries in Africa and Asia, will be defining factors for a scientific conference program that will present latest science from across the globe and discuss its translation into a variety of specific epidemiological and policy contexts. IAS 2017, taking place in Paris on 23-26 July 2017, has an expected attendance of 6,000 to 7,000 delegates from more than 120 countries. The specific aims of IAS 2017 are to: 1. Accelerate basic science and innovation for the development of new prevention, treatment and care options; 2. Strengthen research towards remission off treatment and a vaccine; 3. Enhance knowledge transfer and sharing between HIV and co-infections, including tuberculosis, viral hepatitis, malaria, and co-morbidities; 4. Strengthen the implementation science research agenda to address key barriers and challenges across the HIV prevention and treatment cascades in a variety of epidemic scenarios; 5. Explore the links between HIV and human rights. The scientific program will consist of four tracks: Basic Science; Clinical Science; Prevention Science; Implementation Science. A symposium on HIV cure and cancer research with a further focus on therapeutic vaccines will be organized in conjunction with the conference. Cross-cutting aspects will be covered in plenary talks that also connect the scientific tracks with community and leadership perspectives; bridging sessions cut across at least two of the tracks to provide opportunities for multi-disciplinary dialogues. The participation of young researchers, basic scientists and researchers in related fields such as non-communicable diseases will be strengthened by active solicitation of relevant science and the provision of specific financial support.

项目摘要-在过去几年中取得了重大的科学进步，有助于改善艾滋病毒 预防和治疗成果以及提高成本效益，但仍然存在重大挑战， 破坏实现消除艾滋病这一公共卫生威胁的全球目标：更好的治疗和疫苗 这仍然是应对艾滋病毒/结核病流行的一项紧迫挑战。需要做更多的事情来实现规模扩大， 优化高负担地区的治疗策略。全球在实现雄心勃勃的目标方面仍然面临挑战 在整个护理过程中。迫切需要具体的创新，以改善艾滋病毒检测及其吸收 并成功地将个人保留在终身护理中。这在青少年群体中尤为明显。 IAS 2017将有助于应对艾滋病毒预防、治疗和护理方面的一些持续挑战 在一个科学计划中，将整合创新方法，例如积极应用前卫艺术 基础科学和实施研究的技术，以及作为桥梁主题的精准医学。 法国在艾滋病毒科学方面的关键作用以及能够迅速将科学转化为政策的强大政治意愿， 沿着该国与非洲和亚洲国家的紧密联系，将成为一项科学研究的决定性因素。 一个会议计划，将介绍来自地球仪的最新科学，并讨论其转化为各种 具体的流行病学和政策背景。 IAS 2017将于2017年7月23日至26日在巴黎举行，预计将有6，000至7，000名代表出席 来自120多个国家。IAS 2017的具体目标是： 1.加快基础科学和创新，以制定新的预防、治疗和护理方案; 2.加强研究，以缓解治疗和疫苗; 3.加强艾滋病毒和合并感染，包括结核病、病毒感染、 肝炎、疟疾和合并症; 4.加强科学研究议程的执行，以应对整个世界的主要障碍和挑战。 在各种流行情况下，艾滋病毒预防和治疗级联; 5.探讨艾滋病毒与人权之间的联系。 科学计划将包括四个轨道：基础科学;临床科学;预防科学; 执行科学。艾滋病治疗和癌症研究专题讨论会，进一步关注治疗 疫苗将与会议同时举行。全体会议将讨论贯穿各领域的问题 会谈，也连接科学轨道与社区和领导的观点;桥接会议削减 在至少两个轨道上开展合作，为多学科对话提供机会。的参与 青年研究人员、基础科学家和非传染性疾病等相关领域的研究人员将 通过积极征求相关科学意见和提供具体的财政支持来加强。